Last reviewed · How we verify

Nebulized Fentanyl

Hamad Medical Corporation · Phase 3 active Small molecule

Nebulized Fentanyl is a Opioid agonist Small molecule drug developed by Hamad Medical Corporation. It is currently in Phase 3 development for Acute pain management, Procedural sedation and analgesia. Also known as: Nebulized fentanyl dosage.

Nebulized fentanyl is an inhaled opioid agonist that binds to mu opioid receptors in the central nervous system to provide rapid analgesia and sedation.

Nebulized fentanyl is an inhaled opioid agonist that binds to mu opioid receptors in the central nervous system to provide rapid analgesia and sedation. Used for Acute pain management, Procedural sedation and analgesia.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameNebulized Fentanyl
Also known asNebulized fentanyl dosage
SponsorHamad Medical Corporation
Drug classOpioid agonist
TargetMu opioid receptor (OPRM1)
ModalitySmall molecule
Therapeutic areaPain Management, Anesthesia
PhasePhase 3

Mechanism of action

Fentanyl is a potent synthetic opioid that crosses the blood-brain barrier and activates mu opioid receptors, producing analgesic and sedative effects. The nebulized formulation allows for rapid pulmonary absorption and quick onset of action, making it suitable for acute pain management and procedural sedation. This route of administration bypasses first-pass hepatic metabolism, enabling faster systemic delivery compared to oral routes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nebulized Fentanyl

What is Nebulized Fentanyl?

Nebulized Fentanyl is a Opioid agonist drug developed by Hamad Medical Corporation, indicated for Acute pain management, Procedural sedation and analgesia.

How does Nebulized Fentanyl work?

Nebulized fentanyl is an inhaled opioid agonist that binds to mu opioid receptors in the central nervous system to provide rapid analgesia and sedation.

What is Nebulized Fentanyl used for?

Nebulized Fentanyl is indicated for Acute pain management, Procedural sedation and analgesia.

Who makes Nebulized Fentanyl?

Nebulized Fentanyl is developed by Hamad Medical Corporation (see full Hamad Medical Corporation pipeline at /company/hamad-medical-corporation).

Is Nebulized Fentanyl also known as anything else?

Nebulized Fentanyl is also known as Nebulized fentanyl dosage.

What drug class is Nebulized Fentanyl in?

Nebulized Fentanyl belongs to the Opioid agonist class. See all Opioid agonist drugs at /class/opioid-agonist.

What development phase is Nebulized Fentanyl in?

Nebulized Fentanyl is in Phase 3.

What are the side effects of Nebulized Fentanyl?

Common side effects of Nebulized Fentanyl include Respiratory depression, Dizziness, Nausea, Sedation, Hypoxemia.

What does Nebulized Fentanyl target?

Nebulized Fentanyl targets Mu opioid receptor (OPRM1) and is a Opioid agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing